Patents by Inventor Thurman Wheeler

Thurman Wheeler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Extracellular mRNA Markers of Muscular Dystrophies in Human Urine
    Publication number: 20240084388
    Abstract: Described herein are methods for diagnosing and monitoring subjects with diseases associated with aberrant splicing, based upon detecting properly spliced isoforms and mis-spliced isoforms in a urine sample from the subject.
    Type: Application
    Filed: November 22, 2023
    Publication date: March 14, 2024
    Inventors: Thurman Wheeler, Xandra O. Breakefield, Leonora Balaj
  • Extracellular mRNA markers of muscular dystrophies in human urine
    Patent number: 11866783
    Abstract: Described herein are methods for diagnosing and monitoring subjects with diseases associated with aberrant splicing, based upon detecting properly spliced isoforms and mis-spliced isoforms in a urine sample from the subject.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: January 9, 2024
    Assignee: The General Hospital Corporation
    Inventors: Thurman Wheeler, Xandra O. Breakefield, Leonora Balaj
  • Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
    Publication number: 20230174987
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: July 21, 2022
    Publication date: June 8, 2023
    Applicants: Ionis Pharmaceuticals, Inc., University of Rochester
    Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
  • Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
    Publication number: 20200362353
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: December 20, 2019
    Publication date: November 19, 2020
    Applicants: Ionis Pharmaceuticals, Inc., University of Rochester
    Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
  • Extracellular mRNA Markers of Muscular Dystrophies in Human Urine
    Publication number: 20190284628
    Abstract: Described herein are methods for diagnosing and monitoring subjects with diseases associated with aberrant splicing, based upon detecting properly spliced isoforms and mis-spliced isoforms in a urine sample from the subject.
    Type: Application
    Filed: July 21, 2017
    Publication date: September 19, 2019
    Inventors: Thurman Wheeler, Xandra O. Breakefield, Leonora Balaj
  • MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
    Publication number: 20180163209
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: July 24, 2017
    Publication date: June 14, 2018
    Applicants: Ionis Pharmaceuticals, Inc., University of Rochester
    Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
  • Modulation of dystrophia myotonica-protein kinase (DMPK) expression
    Patent number: 9765338
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: September 19, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
  • Compositions and methods related to protein displacement therapy for myotonic distrophy
    Patent number: 9371527
    Abstract: Disclosed are compositions and methods related to the interaction of polyCUG and polyCCUG repeat RNA and proteins that bind to these repetitive RNA sequences. Also disclosed are methods of treating DM1 or DM2 comprising inhibiting the interaction of poly(CUG)exp or poly(CCUG)exp RNA with muscleblind proteins, or by causing improvement of spliceopathy in myotonic dystrophy.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: June 21, 2016
    Assignee: University of Rochester
    Inventors: Charles A. Thornton, Thurman Wheeler, Krzysztof Sobczak, Robert Osborne, Jill Miller, Maurice Scott Swanson
  • MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
    Publication number: 20160068845
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: July 30, 2015
    Publication date: March 10, 2016
    Applicants: UNIVERSITY OF ROCHESTER, ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
  • Compositions and Methods Related to Protein Displacement Therapy for Myotonic Distrophy
    Publication number: 20150080452
    Abstract: Disclosed are compositions and methods related to the interaction of polyCUG and polyCCUG repeat RNA and proteins that bind to these repetitive RNA sequences. Also disclosed are methods of treating DM1 or DM2 comprising inhibiting the interaction of poly(CUG)exp or poly(CCUG)exp RNA with muscleblind proteins, or by causing improvement of spliceopathy in myotonic dystrophy.
    Type: Application
    Filed: June 5, 2014
    Publication date: March 19, 2015
    Inventors: Charles A. Thornton, Thurman Wheeler, Krzysztof Sobczak, Robert Osborne, Jill Miller, Maurice Scott Swanson
  • MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
    Publication number: 20130237585
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: July 19, 2011
    Publication date: September 12, 2013
    Applicants: UNIVERSITY OF ROCHESTER, ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
  • COMPOSITIONS AND METHODS RELATED TO PROTEIN DISPLACEMENT THERAPY FOR MYOTONIC DISTROPHY
    Publication number: 20100190689
    Abstract: Disclosed are compositions and methods related to the interaction of polyCUG and polyCCUG repeat RNA and proteins that bind to these repetitive RNA sequences. Also disclosed are methods of treating DM1 or DM2 comprising inhibiting the interaction of poly(CUG)exp or poly(CCUG)exp RNA with muscleblind proteins, or by causing improvement of spliceopathy in myotonic dystrophy.
    Type: Application
    Filed: September 21, 2007
    Publication date: July 29, 2010
    Applicants: University of Rochester, University of Florida Research Foundation, Inc.
    Inventors: Charles A. Thornton, Thurman Wheeler, Krzysztof Sobezak, Robert Osborne, Jill Miller, Maurice Swanson